REGION – NAME: CALABRIA – Biotecnomed Scarl 

SECTOR: e-Health

TITLE: Breathless: screening test of lung injury

PROJECT DESCRIPTION

Between 5th and 9th December 1952 in London more than 4000 people already suffering from lung diseases, died due to a thick blanket of smog that stagnated in the city. The most common environmental pollutants are represented by fine powders (from industrial emissions, vehicle exhausts, asphalt and vehicle wear), carbon monoxide (from the combustion processes of vehicles and industrial plants), from nitric oxide and sulfur (which are formed as a result of combustion and are produced by vehicles, industries and domestic and office heating). These substances penetrate the respiratory system and induce the development of lung inflammation resulting in coughing and breathing difficulties that may culminate, if the subject does not move away from exposure, to the development of chronic obstructive diseases such as bronchitis, chronic obstructive pulmonary disease (COPD), emphysema and lung cancer. Moreover, in people who already have a lung disease, exposure to environmental pollutants, even those that are indoor (home heating or cigarette smoke) can worsen the pulmonary state, leading to an increase in hospitalization and the social and health costs associated with it. For airways problems, prescription of antibiotics is often done empirically by physicians.

BUSINESS OPPORTUNITY:

The value proposition of Breathless lies in the advantages it offers compared to organizational aspects. The distinctive benefits are therefore evident:

1-for patients: targeted and more effective therapies and in case of antibiotic therapy reduction of the resistance connected to it.

2-for physicians: reduction of the prescription of inappropriate drugs;

3-for the health service: savings in terms of social costs (WHO HealthStatistics and the Global Burden of Disease study document how in Europe each year about 48 billion euros / year are spent on the treatment of asthma, chronic obstructive pulmonary disease (COPD), lung cancer and pneumonia and this figure reaches about 300 billion euros a year if we consider the value of waiting life lost correct for disability).

Patent for the screening test of lung injury in subjects exposed to environmental toxicants is pending in Italy and an extension to PCT application has been filed.

CONTACT INFO

Name:  Biotecnomed scarl

Website: www.biotecnomed.it 

e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Tel: +39 0961/3694280

Contact person:

Prof. Giovanni Cuda – Dr. Simona Lombardi